Raltegravir
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
HIV Seropositivity
Conditions
HIV Seropositivity, Metabolic Syndrome, Fatty Liver
Trial Timeline
Jan 10, 2018 → Nov 30, 2019
NCT ID
NCT03374358About Raltegravir
Raltegravir is a approved stage product being developed by Merck for HIV Seropositivity. The current trial status is completed. This product is registered under clinical trial identifier NCT03374358. Target conditions include HIV Seropositivity, Metabolic Syndrome, Fatty Liver.
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00377065 | Pre-clinical | Completed |
| NCT03732625 | Approved | UNKNOWN |
| NCT03667547 | Approved | Completed |
| NCT03374358 | Approved | Completed |
| NCT02097108 | Phase 2 | Completed |
| NCT01978743 | Pre-clinical | Completed |
| NCT01767701 | Phase 2 | Completed |
| NCT01453933 | Approved | UNKNOWN |
| NCT01620736 | Phase 2 | Withdrawn |
| NCT01453192 | Phase 3 | Completed |
| NCT01448486 | Approved | Terminated |
| NCT01327482 | Pre-clinical | Completed |
| NCT01325051 | Phase 1 | Completed |
| NCT01042652 | Pre-clinical | UNKNOWN |
| NCT01164605 | Pre-clinical | UNKNOWN |
| NCT01087840 | Approved | Completed |
| NCT01027182 | Phase 1 | Completed |
| NCT00939874 | Approved | Completed |
| NCT00807443 | Phase 2 | Completed |
| NCT00887653 | Phase 3 | Completed |
Competing Products
2 competing products in HIV Seropositivity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| poly I-poly C12U | AIM ImmunoTech | Phase 2 | 25 |
| poly I-poly C12U | AIM ImmunoTech | Phase 2 | 17 |